Cross-sex hormonal treatment in transgender persons does not decrease areal bone density; a 2 year follow-up study

Background

* Both first authors have contributed equally to this paperGiven the importance of adequate sex steroid exposure for skeletal health, bone metabolism should be a focus of interest in transgender persons. Previous studies... [ view full abstract ]

Aim(s)

To evaluate areal bone mineral density (aBMD) in transgender persons before initiation of cross-sex hormonal treatment and after one and two years. [ view full abstract ]

Main Outcome Measures

This study is part the endocrine part of the European Network for the Investigation of Gender Incongruence (ENIGI). Belgian data of 148 trans women and 84 trans men were analyzed. [ view full abstract ]

Methods

Before administration of cross-sex hormones and after one and two years, aBMD was assessed by DXA scanning at the lumbar spine and proximal femur. [ view full abstract ]

Results

Trans women were older (32.6 years) than trans men (26.0 years). In trans women, aBMD had increased after one year (baseline: 0.97 ± 0.14 g/cm2, 0.94 ± 0.14 g/cm2 and 0.81 ± 0.13 g/cm2 at lumbar spine, total hip and... [ view full abstract ]

Conclusion

We present for the first time prospective data on aBMD in a large group of transgender persons after two years of cross-sex hormonal therapy. Our results indicate that cross-sex hormones do not negatively affect bone mass in... [ view full abstract ]

Authors

Justine Defreyne (Ghent University Hospital, Department of Endocrinology), Josefien Hoedt (Ghent University), Chantal Wiepjes (VU), Eva Van Caenegem (Ghent University), Bruno Lapauw (Ghent University), Stefan Goemaere (Ghent University), Hans Zmierczak (Ghent University), Guy T'Sjoen (Ghent University Hospital, Department of Endocrinology and Center for Sexology and Gender, Ghent)

Topic Area

Oral & Poster Topics: Endocrinology

Session

OS-1C » Endocrinology I (14:00 - Thursday, 6th April, Atlantic 3)

Presentation Files

EPATHDefreyneJustineBONE.pptx